Note 9 — Share-Based Compensation

Stock Options

During the three months ended March 31, 2026, no option awards were granted and no options were forfeited. As of March 31, 2026, 7,634 option awards remained outstanding with a weighted average exercise price of $266.67. During the three-months ended March 31, 2025, no option awards were granted and 720 option awards were forfeited. As of March 31, 2025, 22,735 option awards remained outstanding with a weighted average exercise price of $265.60.

Restricted Stock Units

During the three months ended March 31, 2026, the Company granted no restricted stock units (“RSUs”). The Company’s RSUs are based on the fair value of the Company’s common stock on the dates of grant. During the three months ended March 31, 2025, 40,016 RSUs were granted at a weighted average price of $68.00.

The RSUs granted in the three months ended March 31, 2025 primarily vested one-fourth of the award value on the date of grant, with the remaining restricted shares vesting in equal installments on January 1, 2026, January 1, 2027, and January 1, 2028.

​

The Company recognized share-based compensation expense related to RSUs of $122 and $827 for the three months ended March 31, 2026 and March 31, 2025, respectively, under Share-based compensation expense on the Condensed Consolidated Statements of Operations. During the three months ended March 31, 2026 and March 31, 2025, the Company’s non-employee directors earned $60 and $80, respectively, in compensation for their service on the Company’s board of directors, which was recognized under Share-based compensation expense on the Condensed Consolidated Statements of Operations.

​